Journal of Medicinal Chemistry · 2015 · 94 citations · 35 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyChemotherapyDrug DiscoveryChemotherapy ResistanceCytochrome P450 EnzymesCytochrome P450-mediated MetabolismEnzyme InhibitionOncology PharmacologyStructure-activity Relationship AnalysisAnticancer Drug ResistanceCytochrome P450 1A2Cytochrome P450 Enzyme InhibitionCytochrome P450 ResistanceCytochrome P450 Structure-function RelationshipsDrug Resistance Modulation
CYP1B1 is recognized as a new target in cancer prevention and therapy. Taking α-naphthoflavone as a lead, a series of 6,7,10-trimethoxy-α-naphthoflavones (4a-o) were synthesized and evaluated for their inhibitory potency against CYP1B1 and selectivity over CYP1A1 and 1A2. SAR analysis indicated that introducing methoxy groups at C(6), C(7), and C(10) on the naphthalene part and a fluoro atom at C(3') on the B-ring, could sharply increase the efficiency toward CYP1B1 inhibition. Among the prepared derivatives, compound 4c is the most potent and selective CYP1B1 inhibitor ever reported. More effort was taken to acquire water-soluble α-naphthoflavone derivatives for further cell-based study of overcoming anticancer drug-resistance. Finally, we obtained water-soluble naphthoflavone (11f) which could obviously eliminate the docetaxel-resistance caused by the enhanced expression of CYP1B1 in MCF-7/1B1 cells. It could be envisaged that the discovery of new α-naphthoflavones as CYP1B1 inhibitors is clinically important for overcoming CYP1B1-mediated drug-resistance in cancer therapeutics.
35
Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
Tsutomu Shimada, Carrie L. Hayes, Hiroshi Yamazaki et al. · PubMed · 1996 · 795 citations
Pharmacy, Biochemistry, Toxicology +17
Tumor-specific expression of cytochrome P450 CYP1B1.
Graeme I. Murray, M C Taylor, Morag McFadyen et al. · PubMed · 1997 · 534 citations